Seeking Alpha

Biogen Idec (BIIB +2%) and Isis Pharmaceuticals (ISIS +2.8%) enter into an agreement to develop...

Biogen Idec (BIIB +2%) and Isis Pharmaceuticals (ISIS +2.8%) enter into an agreement to develop and commercialize an antisense drug for the treatment of Steinert disease. Isis will receive an upfront payment of $12M and is responsible for the discovery of a lead drug candidate. In all, the deal could see Isis rake in more than $271M.
Comments (6)
  • arthurs1
    , contributor
    Comments (343) | Send Message
     
    Seems to be a beneficial and expanding relationship. Look for more ISIS partnership and pipeline news this year.
    29 Jun 2012, 01:29 PM Reply Like
  • rwbfacs
    , contributor
    Comments (4) | Send Message
     
    Is it true that ISIS could be very profitable just with 4 0r 5 deals like this one per year and then the ensuing royalties?.
    29 Jun 2012, 01:54 PM Reply Like
  • rwbfacs
    , contributor
    Comments (4) | Send Message
     
    Semiretired physician(General Surgeon)
    Longtime investor in ISIS
    29 Jun 2012, 01:54 PM Reply Like
  • rwbfacs
    , contributor
    Comments (4) | Send Message
     
    I'm a semi retired General Surgeon and a longtime fan(investor) of ISIS
    29 Jun 2012, 01:54 PM Reply Like
  • kk9430
    , contributor
    Comment (1) | Send Message
     
    As a former medical librarian, I am pleased to see a company doing good for patients resulting in profits for the investors as well.
    1 Jul 2012, 02:58 PM Reply Like
  • arthurs1
    , contributor
    Comments (343) | Send Message
     
    You can follow a very good and active message board with all the moving Isis parts here.
    http://bit.ly/JC0uFl
    1 Jul 2012, 04:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|